Uroplasty, Inc. has received an approvable letter from the  FDA relating to its pre-market approval application for Macroplastique implants  for the treatment of female stress urinary incontinence.

The product is a soft tissue, injectable bulking agent for  use in a minimally invasive, outpatient procedure. When a physician injects  Macroplastique into the tissues surrounding the urethra, the increased bulk  allows the urethra to close more effectively and prevents urine from leaking,  the company said.

News

Cosmetic Surgery

Uroplasty, Inc. has received an approvable letter from the FDA relating to its pre-market approval application for Macroplastique implants for the treatment of female stress urinary incontinence.